L’Oréal has acquired a majority stake in British skincare brand Medik8, the companies announced Monday. The brand will be managed under the beauty giant’s Luxe division, sitting alongside premium lines like Aesop and Kiehl’s. The terms of the transaction were not disclosed, though a recent report in the Financial Times said the brand was valued at roughly $1 billion.
Medik8, which was founded in 2009 by Elliot Isaacs, sells science-backed serums that are designed to preserve and restore skin, including its popular Liquid Peptides ($66) and Crystal Retinal ($85) ranges. It has a production and research facility in Buckinghamshire, England, where it manufactures its products.
In 2021, Medik8 was acquired by private equity firm Inflexion. Sales reached $70 million to $80 million in 2024, following a push into the US market.
Science-backed skincare has been a boon for L’Oréal, which also owns other “dermocosmetics” brands like the mass lines Cerave and La Roche Posay, as well prestige names like Skinceuticals and Skinbetter Science.
“We share a strong belief in Medik8’s global potential,” said Cyril Chapuy, president of L’Oréal Luxe, in a statement.
Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day’s most important beauty and wellness news and analysis.
Learn more:
Beauty’s Top M&A Targets for 2025
After a slow year for acquisitions, brands and investors alike are hoping that 2025 will yield bigger exits. But with most strategic buyers like L’Oréal operating with an even narrower lens, only a select few firms will make it across the finish line.
